Search

Displaying results 2441 - 2450 of 8575 in total
  1. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    [L53408] As opposed to previously approved COVID-19 mRNA vaccines, including the original [Moderna COVID-19 Vaccine], mRNA-1283 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV- … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  2. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]

  3. Drug

    Aspartame

    go.drugbank.com/drugs/DB00168
    InvestigationalNutraceutical

    Flavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid.

  4. Drug

    Ethoheptazine

    go.drugbank.com/drugs/DB08988
    ApprovedWithdrawn

    It was invented in the 1950s and is related to other drugs such as proheptazine. Ethoheptazine is no longer marketed in the United States.

  5. Drug

    Calcium acetate

    go.drugbank.com/drugs/DB00258
    Approved

    It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form.

    Products: CALCIUMACETAT NEFRO 500MG, CALCIUMACETAT NEFRO 700MG
  6. Drug

    Diphenylguanidine

    go.drugbank.com/drugs/DB14191
    Approved

    Diphenylguanidine is a complexing agent used in the detection of metals and organic bases and used as an accelerator in the vulcanization of rubber. It is found in some rubber products.

  7. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.

  8. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    [A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults.

  9. Drug

    Rabies immune globulin, human

    go.drugbank.com/drugs/DB11603
    Approved

    Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun. … If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies

  10. Drug

    Metocurine

    go.drugbank.com/drugs/DB01336
    Approved

    Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant.